IBA Déclaration Intermédiaire – Premier Trimestre 2019

NEXT STORY
Roche to present new OCREVUS (ocrelizumab) data analyses showing significant reduction of disability progression in relapsing and primary progressive multiple sclerosis at the AAN Annual Meeting
PREV STORY
OPKO Health Reports 2019 First Quarter Business Highlights and Financial Results
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

NeuBase Therapeutics Appoints Todd P. Branning Chief Financial Officer

author_avatar
NASDAQ Market News

Genmab Announces Abstracts Evaluating Products in Pipeline, Portfolio to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Congress

author_avatar
NASDAQ Market News

BioAegis Therapeutics and the T.H. Chan-Harvard School of Public Health Demonstrate “Delayed Therapy with Plasma Gelsolin Improves Survival in Murine Pneumococcal Pneumonia” at ID Week

MORRISTOWN, N.J. and BOSTON, Oct. 18, 2017 (GLOBE NEWSWIRE) -- (BIOAEGIS THERAPEUTICS)BioAegis Therapeutics Inc., ...

author_avatar
NASDAQ Market News